AsymBio

Website | LinkedIn | Contact Us

AsymBio's Services for Early-Stage Drug Development

CHO-K1 Transient Expression and Purification Capabilities

*Timeline starts with sequence synthesis and includes QC testing

Expression Strategy	Equipment	Titer	Timeline*	Purification	Throughtput	Test Items
Transient	Spin tubes/ flasks	~1-2 g/L	2 weeks	Gravity chromatography	10/batch	A280, SEC-HPLC SDS-PAGE LC-MS, CE-SDS, etc. (optional)
Stable	Flasks	~4 g/L	5 weeks	AKTA	3/batch	

CHO-K1 Transient Expression and Purification Capabilities

Scale	Rounds	Timeline*	Purification	Throughtput	Test items**
1~10mg	1~2	1~2 weeks	UF/DF/ Chromatography (Optional)	10+	DAR、SEC、protein concentration(required) Free-drug、endotoxin
100mg	2	2 weeks	UF/DF / Chromatography (Optional)	3~5	
1~10g	2~3	3 weeks	TFF / Chromatography (Optional)	1~3	

Experience Across Commonly Used Payloads and Linkers

vcMMAE	CL2A-SN38	mcMMAF	Tesirine	MC-GGFG-DXd	SPBDDM4
MC-GGFG-Exatecan	SMCC-DM1	MC-β-Glucuronide -MMAF	MC-β-Glucuronide -Exatecan	DBCO-PEG3-VC -Exatecan	Mal-PEG2-Val -Cit-PAB-eribulin

Applicable to new modality or specifically designed molecules

Mutiple Modalities



Advanced platform for material preparation

Stress conditions simulating manufacturing, storage, and delivery

Customized Stress and Stability Studies

State-of-the-art analytical platform

Seamless Transition from Drug Discovery to Early CMC Development

Featured Developability Assessment

- Lead Candidate Prioritization
- Formulation Feasibility Assessment
- Identification of Critical Quality Attributes
- Understanding Candidate Degradation Pathways

Rich experience on various DP dosage forms

CDMO Your Trusted Biologics CDMO